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Fumonisins—mycotoxins produced by
several Fusarium species, especially Fusarium
verticillioides (F. moniliforme) and prolifera-
tum—have been reported in animal foods
and corn-based human foods from around
the world (1,2). Fumonisins alter sphin-
golipid biosynthesis, induce hepatotoxicity,
and elevate serum cholesterol concentration
in all species studied. Other effects are species
speciﬁc: pulmonary edema and cardiovascular
changes in pigs, leukoencephalomalacia in
horses, and renal injury in sheep, rabbits, and
rats (3–10). Mycotoxin-induced pulmonary
edema was ﬁrst documented in swine in 1981
after they were exposed experimentally to
corn contaminated by F. verticillioides (11).
In the midwestern and southeastern parts of
the United States, thousands of pigs died
from pulmonary edema after ingesting corn
contaminated by fumonisins from the 1989
corn crop. Thus, the disease was designated
porcine pulmonary edema (PPE). Abortions
also were reported in some affected herds
(12). This outbreak was caused by high con-
centrations of fumonisins present in corn
following a hot dry summer. Corn screenings
obtained from Georgia and Iowa farms with
outbreaks of fatal pulmonary edema con-
tained fumonisin (F)B1 at 155 and 92 parts
per million (ppm), respectively, and, when
experimentally fed to pigs, produced severe
pulmonary edema and hydrothorax within 7
days, as well as liver damage (4,12,13). A
recent report suggests that this disease has
been recognized since the 1950s in Hungary,
where it is known as “fattening or unique
pulmonary edema of pigs” (14). Pulmonary
edema has been reproduced following experi-
mental exposure of swine to fumonisin-con-
taining culture material and purified FB1
given orally or intravenously (4,15,16).
Abnormal climatic conditions in the U.S.
Midwest were responsible for the very high
levels of fumonisins in the 1989 corn crop.
Since that time, the overall levels of fumon-
isins in corn have been lower. In a U.S.
Department of Agriculture (USDA) study of
the 1995 Midwest corn crop (preharvest sam-
ples), 7% of the crop contained > 5 ppm FB1,
40% 0.5–5 ppm, and 54% < 0.5 ppm (17).
The highest concentration of FB1 was 24
ppm and the average 1.5 ppm. In a survey
carried out from 1996 to 1999 in south
Georgia, up to 91% of the samples con-
tained fumonisins; 30 % of samples had
concentrations > 1 ppm, and the highest
concentration was 33 ppm (18). A World
Health Organization working group found
that globally 59% of corn and corn product
samples were contaminated by FB1 (19). 
Whereas initial studies focused on repro-
duction of the spontaneous disease and its
characterization, subsequent research has
addressed the pathogenesis of pulmonary
edema and effects of longer-term ingestion of
low doses of fumonisin. Physiologically, the
two main causes of pulmonary edema are left
ventricular failure, which increases pul-
monary capillary hydrostatic pressure, and
increased vascular permeability after injury to
the alveolar capillary endothelium or alveolar
epithelium. Structural changes may be absent
in either case. The pathogenesis of fumonisin-
induced pulmonary edema in swine must
account for the species speciﬁcity of the lesion
because pulmonary edema has been docu-
mented only in swine. In addition, the role of
altered sphingolipid biosynthesis must be con-
sidered. Understanding the pathogenesis of
pulmonary edema is important in both pre-
venting and treating PPE as well as in under-
standing the mechanism of fumonisins’
species-speciﬁc effects. Perhaps more impor-
tant than PPE, which occurs only at high-
level exposure, are the effects of long-term
exposure to low concentrations of fumon-
isins in the diet, because this occurs more fre-
quently and involves larger numbers of
animals. Mycotoxins commonly are immuno-
suppressive, and an association between
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fumonisin contamination and infectious
disease in swine has been reported (20). 
Because swine are excellent models for
human cardiovascular and other diseases, the
mechanism for fumonisin toxicosis in swine
must be characterized to permit assessment of
its potential toxicity in human populations.
This assessment includes characterizing the
hepatic, cardiovascular, and hypercholes-
terolemic effects of fumonisin ingestion in
swine as well as interaction with other agents,
both infectious and toxic. In humans, epi-
demiologic association of high-level fumon-
isin exposure with esophageal cancer (21) is
well known and has recently been described
for neural-tube defects linked to fumonisin-
induced folate deﬁciency (22).
Pharmacokinetics of FB1
and Residue Localization
Because availability of puriﬁed FB1 is limited,
the most extensive studies have been per-
formed in rodents. In rats, fumonisins are
absorbed poorly and excreted rapidly (appar-
ently as parent compound) by the liver and to
a much lesser degree through the kidney
(23–26). The pharmacokinetics of [14C]FB1
in swine are as follows: 
• Half-life: α, 2 min; β, 10 min; γ, 182 min
• Volume of distribution: 2.4 L/kg (widely
distributed)
• Plasma clearance: 9.1 mL/min/kg (mod-
erate rate)
• Absorption: 3–6% (poor bioavailability)
• Excretion (recovery at 72 hr)—mainly fecal
(60%), urine (20%), total (80%)—biliary
excretion with enterohepatic recycling
• Distribution (specific activity at 72 hr):
liver >> kidney > large intestine > brain >
lung, heart, adrenal gland, spleen (27,28). 
In swine, plasma radioactivity declined in
a triexponential manner following intra-
venous administration of [14C]FB1 with a
large volume of distribution (2.4 L/kg) and
moderately rapid plasma clearance (9.1
mL/min/kg) (27). Only trace levels of
radioactivity remained in plasma after 3 days.
As in rats, FB1 was eliminated primarily in
the feces of swine (58% recovery) and to a
much lesser extent in the urine (21%).
Fumonisin tissue residues 72 hr after admin-
istration were greatest in liver >> kidney >
large intestine > brain > lung, heart, and
adrenal gland. In bile-cannulated pigs, bile
recovery was 71% and the γ phase was
absent, indicating enterohepatic recirculation
of the toxin. When FB1 was given intragastri-
cally, bioavailability was 3–6%. After 3 days,
the total remaining tissue residues were 10-
to 20-fold lower than after the intravenous
dose (27). Fumonisin residues accumulated
in liver and kidney when pigs were fed
[14C]FB1 at dietary concentrations of 2–3
ppm for 24 days (28). When this was
followed by clean food, radioactivity
decreased rapidly to 35% of peak values after
3 days, with only trace levels after 9 days.
Interestingly, fumonisin excretion was
< 35% of intake during the first 3 days of
feeding, but then increased to 70–85% of
the daily intake for the remainder of the trial.
Therefore, FB1 has very poor oral bioavail-
ability in swine, although the fraction that is
absorbed undergoes wide distribution and
has specific affinity for the liver and to a
lesser extent the kidney. Furthermore, the
half-life of absorbed fumonisins is relatively
long because of enterohepatic recirculation
and to a lesser extent the uptake and slow
release of the toxin by the liver and kidney.
Therefore, diets containing FB1 that are con-
sumed over extended periods may result in
the accumulation of potentially toxic residues
in liver and kidney. Pigs exposed to dietary
FB1 at 2–3 ppm would require a withdrawal
period of at least 2 weeks to ensure that only
minimal residue levels remained (28).
Overview of Fumonisin
Toxicosis
Fumonisin toxicosis in swine is characterized
by injury to the pulmonary, hepatic, cardio-
vascular, and immune systems as well as early
and widespread alteration of sphingolipid
metabolism and effects on growth rate and
carcass composition. Pigs develop lethal pul-
monary edema within 4–7 days when fed FB1
containing feed or culture material at concen-
trations of ≥ 92 ppm or ≥ 16 mg/kg body
weight/day (4,15,16,29,30). Similarly, lethal
pulmonary edema occurs within 7 days after
daily intravenous administration of FB1 (4).
In many studies using feed or culture material,
only the concentration of FB1 is given.
However, generally FB1 and FB2 are produced
together, with FB2 representing 15–35% of
the amount of FB1 (31). In rats, similar effects
were produced by FB1, FB2, and FB3 in cul-
ture material, with severity of response in the
order FB1 > FB2 > FB3 (32). We recommend
that equal consideration be given to FB1, FB2,
and FB3 for risk assessment and management
purposes until data to the contrary are
obtained (32). Therefore, the presence of FB1,
FB2, and FB3 should be taken into account in
any toxicity calculations.
In contrast to most studies in which
pulmonary edema is observed in pigs only
during the first week of high-dose FB1
ingestion, pulmonary edema of increasing
severity was identified by computer tomo-
graphic and pathologic examination in
weanling pigs fed lower doses of FB1 as cul-
ture material (10–40 ppm) for 4 weeks (33).
However, pigs did not show any clinical
signs of toxicity. Pulmonary edema also was
observed in piglets from two sows fed 300
ppm FB1 as culture material for 14 days,
from day 107 of gestation to 7 days after
parturition (34). 
Clinically, inactivity, increased respiratory
rate, and decreased heart rate occur approxi-
mately 12 hr before the development of pul-
monary edema and death (35). Respiratory
distress, manifested as increased respiratory
rate and effort with abdominal and open-
mouth breathing, occurs within hours of
death; vomiting and diarrhea also have been
observed (15,16). At necropsy, pulmonary
edema is present and can be quantitated as
increased lung wet/dry weight ratio. Although
cardiovascular abnormalities were not
detected using electrocardiographic and
pathologic evaluation (15,29), we recently
identified hemodynamic changes indicating
cardiovascular injury that precede the onset of
pulmonary edema and presumably are
causative (9,10,35–37). 
Pigs ingesting fumonisin develop hepatic
injury that is dose- and time-dependent and
can be detected as elevated hepatic serum
enzyme activity and morphologic alteration
(15,16,29,30). Serum biochemical changes
indicate hepatic necrosis, cholestasis, and
decreased hepatic function. Clinically, pigs
with severe liver disease become anorexic and
icteric, may lose weight, show signs of
encephalopathy, and become moribund
(12,15). The earliest and most specific bio-
chemical change is an increase in serum and
tissue sphingoid bases (sphingosine and sphin-
ganine) that is time- and dose-dependent
(16,35,38). This is caused by the inhibition of
ceramide synthase by fumonisin that inhibits
sphingolipid biosynthesis with resultant
increases in sphingoid base concentrations in
tissues and serum (39).
Pigs fed 100–193 ppm FB1 in culture
material for at least 93 days developed hepatic
nodular hyperplasia (2/3 studies), hyperplastic
esophageal plaques (1/3 studies), gastric ulcer-
ation, hypertrophy of the heart and medial
hypertrophy of the pulmonary arteries (1/3
studies) (6,40,41). The cardiovascular changes
occurred in four pigs receiving 150–170 ppm
FB1 from culture material in the diet for up to
217 days (6). Histopathologic alterations were
not observed in the hearts. The cardiovascular
changes suggest pulmonary hypertension,
although pulmonary hypertension has been
documented only in short-term, high-dose
studies (9,10,35,37).
Variable effects of fumonisins on food
consumption and feed efficiency have been
reported. Although decreased food consump-
tion often is seen with naturally contaminated
corn, presumably due to palatability problems
(29,30), observations with FB1, either as pure
compound or in culture material, have been
variable; no effect as well as increased and
decreased feed consumption and weight gain
have been reported (28,42–44). Decreased
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feed efficiency may be caused by increased
oxygen consumption (10,35). Increased vari-
ability of carcass quality was reported with
ingestion of FB1 at 1 ppm (44). 
Clinical Pathology
Alterations in hepatic serum biochemical
parameters, including serum bile acids, biliru-
bin concentration, and aspartate aminotrans-
ferase, alkaline phosphatase, gamma-glutamyl
transferase, lactate dehydrogenase, and
arginase activities reflect toxicity to the liver
that is time- and dose-dependent (9,10,15,
16,29,30,40). Serum hepatic biochemical
alterations were observed with FB1 and FB2
as low as 12 ppm in the diet (30). Increased
serum cholesterol concentration is a feature of
fumonisin toxicity and has been reported at
≥ 1 ppm FB1 (15,16,29,30,40,43,44). Slight
increases were reported after 11 weeks in
nonfasted (but not in fasted) pigs at a dietary
concentration of 1 ppm FB1 (44); however,
the same research group fed pigs a ration con-
taining 10 ppm, and after 8 weeks the mean
cholesterol values in both sexes were less than
those of controls (43). Hypercholesterolemia
appears to be the most sensitive serum bio-
chemical parameter to fumonisin exposure.
Hematologic proﬁles remain within the nor-
mal range in fumonisin-treated pigs (30,43). 
Sphingolipid Alterations
Fumonisins and fumonisin analogs inhibit
sphinganine (sphingosine) N-acyltransferase
(ceramide synthase), an enzyme of critical
importance in sphingolipid biosynthesis,
increasing the concentration of sphingoid
bases (sphinganine and sphingosine) and
depleting complex sphingolipids (39,45).
Because the alteration in cellular concentra-
tions of these molecules is proposed as the
mechanism of fumonisin toxicosis (46,47), it
has been important to document the organ
specificity, dose response, and temporal
changes in these compounds and to relate
these changes to the effects of fumonisins in
cells and tissues. 
Fumonisin exposure in swine causes a
dose- and time-dependent elevation in the
concentration of free sphinganine, and to a
lesser extent sphingosine, with a correspond-
ing increase in the sphinganine-to-sphingosine
ratio, in serum and tissues (16,35,38).
Increased sphinganine-to-sphingosine ratios
were present in pig tissues (lung, liver, and
kidney) at ≥ 23 (but not 5) ppm and in serum
at ≥ 5 ppm total fumonisins from naturally
contaminated corn after a 14-day exposure
(38). Similar increases in sphinganine and
sphingosine concentrations were induced with
puriﬁed toxin in tissues and serum of pigs fed
FB1 at 1.5 mg/kg/day for 5 days (42) and in
tissues at 10 (but not ≤ 1) ppm for 8 weeks
(43). In a temporal study, the concentration
of sphingoid bases increased in pig tissues after
only one day of feeding culture material con-
taining FB1 at 20 mg/kg body weight and
before appearance of histologic changes in
liver and lung, which were detectable at day 2
[Figure 1 (16)]. Sphinganine levels plateaued
in virtually all organs, as well as serum, by day
2 or 3 while sphingosine continued to increase
progressively. Depletion of sphingosine con-
taining complex sphingolipids with an
increase in sphinganine containing complex
sphingolipids in the liver has been reported
(38). Similar alterations in sphingosine and
sphinganine concentrations have been
observed in other species (8,48,49) but not
with any other toxicant class.
Based on pharmacokinetic studies, there
is some correlation between the magnitude of
sphingolipid alterations in tissues and the dis-
tribution of FB1, which is greatest in liver and
kidney (27). Changes in the sphinganine-to-
sphingosine ratio in short-term swine studies
generally have been in the following order:
kidney, liver > heart > lung >> other tissues
such as lymph node and skeletal muscle
(16,35,38,42); however, in a low-dose,
longer-term study the magnitude was lung >>
kidney, liver (43). In general, the kidney
appears to be the most sensitive organ to
fumonisin-induced sphingolipid alterations in
all species examined, regardless of its sensitiv-
ity to morphologic and functional damage in
that species (38,48,49). Unlike in rabbits,
sheep, and rats, where kidney is the primary
target organ (5,7,8), in swine, renal injury has
been reported inconsistently (14,15). This
may relate to cell-speciﬁc functions of sphin-
golipids in the same organ in different
species. Sphingoid bases increased in serum
earlier (within 24 hr) (16) and at lower doses
of fumonisin (≥ 5 ppm) (38) than serum liver
enzymes and before morphologic tissue alter-
ations, suggesting that serum concentrations
of sphingoid bases could be used as a sensitive
biomarker of fumonisin exposure. The role of
altered sphingolipid biosynthesis in the
pathogenesis of fumonisin toxicity currently
is under investigation.
Pulmonary Pathology and 
in Vitro Studies
Pigs that die in respiratory distress have
pulmonary edema characterized grossly by
heavy, wet lungs with widened interlobular
septa as well as fluid in the airways and the
thoracic cavity; this ﬂuid is a modiﬁed transu-
date (4,16,29,30). Histologically, the major
alteration is the presence of clear fluid and
markedly dilated lymphatics in connective tis-
sue around vessels and bronchi, subpleurally,
and in interlobular septa (Figure 2). In more
severe cases, protein may be present in the
edema ﬂuid and this ﬂuid may be observed in
alveoli and even in airways. Inflammation is
not a feature of the disease. 
Ultrastructurally, alterations that indicate
permeability changes have not been observed
in the pulmonary vasculature. However,
accumulation of membranous material
(multilamellar bodies) was found within pul-
monary intravascular macrophages in pigs
with pulmonary edema (15,29). In a more
detailed study where lung was ﬁxed intravas-
cularly, the primary site of these membranous
accumulations was identified as the pul-
monary capillary endothelial cell; this alter-
ation was observed as early as 2 days after
initiation of exposure (16). Occasionally,
affected endothelial cells were electron dense
and shrunken, i.e., undergoing apoptosis.
Phagocytosis of these dying endothelial cells
by pulmonary intravascular macrophages
resulted in the membranous material being
localized within phagosomes of these cells.
This membranous material may be the result
of sphingoid base accumulation with damage
to the cytocavitary network. This membra-
nous material was observed in pigs given
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Figure 1. Sphingosine (A) and sphinganine (B) concentrations in tissues and serum of pigs fed fumonisin-containing
culture material at a dose of 20 mg FB1/kg/day (16). Sphinganine increases over time reaching a plateau or declining
on the last day, whereas the increase in sphingosine is progressive and continual. Bars represent the mean value
(error bars = SD); n = 4–6 pigs. 
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purified FB1 intravenously (50) and in pigs
fed fumonisin containing culture material at
doses that did not induce pulmonary edema
(15,50), indicating that these alterations were
induced by FB1 but did not necessarily cause
pulmonary edema. Similar capillary endothe-
lial changes were not observed in any other
species (50) nor have they been reported for
any other toxin; therefore this alteration
appears specific for fumonisin exposure in
swine. Following chronic exposure to
fumonisins, medial pulmonary arterial
hypertrophy indicative of hypertension has
been observed (6).
The effects of fumonisins on pulmonary
endothelial cells have been examined in in
vitro studies. Increased albumin permeability
occurred in cultured porcine pulmonary
artery endothelial cells within 12 hr of expo-
sure to 30 or 50 mM FB1 (51), doses much
higher than expected in plasma of pigs dying
from pulmonary edema. Cell viability
appeared to decrease proportionately to the
increase in albumin permeability, suggesting
that cell death was responsible for the
increased permeability. The cell cultures incu-
bated with FB1 at 50 mM had elevated sphin-
ganine concentrations by 3 hr and an elevated
sphinganine-to-sphingosine ratio by 24 hr
(51). Neither toxicity nor ultrastructural
changes were observed when we incubated
porcine pulmonary endothelial cells with FB1
at doses within the range anticipated for in
vivo exposure, 5–20 µg/mL for 10 or 7 days,
respectively (52).
Cardiovascular Toxicity 
In early acute studies of fumonisin exposure,
the cardiovascular system was examined using
morphology and electrocardiography because
pulmonary edema frequently is secondary to
cardiovascular damage (15,29). Because alter-
ations were not observed in these studies, the
focus of subsequent studies examining the
pathogenesis of pulmonary edema shifted
to the lung. However, right ventricular
hypertrophy and medial hypertrophy of small
pulmonary arteries, suggesting pulmonary
hypertension, were observed in a chronic
study where pigs were fed 100–190 ppm FB1
for up to 210 days (6). Cardiovascular
changes were not observed in a similar study
lasting 93 days (40).
The chronic cardiovascular ﬁndings stim-
ulated more detailed examination of the
potential effects of fumonisins on cardiovas-
cular function, using pigs instrumented to
facilitate hemodynamic measurements
(9,10,35–37,53). Pigs fed culture material
containing fumonisins at ≤ 20 mg/kg body
weight for 3–7 days had increased mean pul-
monary arterial pressure and decreased heart
rate, cardiac output, and mixed venous oxy-
gen tension (9,10,35,37). In addition, treated
pigs had decreased cardiac contractility as
assessed by left ventricular dP/dtmax (10) and
end-systolic elastance (36,37), the gold stan-
dard in vivo measure of cardiac contractility.
Plasma sphinganine and sphingosine concen-
trations were increased by 24 hr and contin-
ued to increase over time; sphinganine and
sphingosine also markedly increased in car-
diac muscle (35). Intravenous administration
of purified FB1 to swine similarly decreased
cardiovascular function; however, the perme-
ability of the alveolar-capillary membrane, as
measured by Evans blue dye clearance, was
not altered (35). Fumonisin ingestion also
directly relaxed systemic arteries, leading to
systemic arterial hypotension (53). Therefore,
FB1 is a negative inotropic and chronotropic
agent that also relaxes vascular smooth mus-
cle, leading to decreased cardiovascular
reserve in pigs. Decreased cardiac contractility
would appear responsible for increasing pul-
monary artery wedge pressure (an index of
pulmonary capillary pressure) and subsequent
pulmonary edema.
Hepatic Pathology
Fumonisins cause hepatic injury in all species
regardless of the route of administration. In
swine, morphologic alterations were observed
following ingestion (≥ 23 ppm) (30) or intra-
venous administration (4,12,29). Acute
hepatic changes include disorganization of
hepatic cords, hepatocellular vacuolation,
megalocytosis, apoptosis, necrosis, and cell
proliferation [Figure 3 (4,12,15,16,29,30)].
These changes appear to be most marked in
centrilobular and midzonal regions (16).
Ultrastructurally, accumulations of membra-
nous material (multilamellar bodies) similar
to those found in the lung have been reported
within hepatocytes and Kupffer cells (29).
In pigs with clinical manifestation of
liver failure, similar but more severe liver
changes were observed (15). Liver damage
was reversible following removal of the toxin
in a small group of pigs (15). In chronic
feeding studies—100–193 ppm FB1 in
culture material for a minimum of 93
days—hepatic necrosis (without bile duct
proliferation), fibrosis, and nodular hyper-
plasia were observed (6,40,41).
Other Organ-Speciﬁc
Alterations
Miscellaneous and inconsistent findings
reported include pancreatic acinar cell apop-
tosis and necrosis (4,12,29,30) with membra-
nous intracytoplasmic material (multilamellar
bodies) similar to that found in the pul-
monary capillary endothelial cells (29).
Histologic evidence of renal tubular injury
(14,15) has been inconsistently reported and
could be secondary to severe hepatic injury
(bile nephrosis). More extensive evaluation
of renal function, including clearance
studies, indicates that direct fumonisin-
induced nephrotoxicity does not occur (35).
Encephalomalacia in one of two pigs that
developed fatal pulmonary edema was
reported in one study using culture material
(14). Hyperplasia of the basal cell layer of the
distal esophageal mucosa was reported in 6/6
pigs and hyperplastic plaques in 1/6 pigs fed
100–193 ppm FB1 in culture material for 93
days (40). In the same study, gastric ulcera-
tion was present in 6/6 pigs. Esophageal
changes are of interest because of the epi-
demiologic association between ingestion of
FB1 and esophageal cancer in humans (18).
Immunotoxicity 
Although the immunosuppressive effects of
mycotoxins such as T-2 toxin and aflatoxin
are well known (54,55), only limited informa-
tion is available regarding the effects of
fumonisins on the immune system, especially
in swine. In mice, fumonisins can be either
immuno-stimulatory or immuno-suppressive
depending on the dose of FB1 and period of
exposure (56). In swine, short-term ingestion
of fumonisin (up to 3 weeks) did not affect
specific immunity (12,57) but longer-term
ingestion (4–8 weeks) produced an adverse
effect (40,58,59). We fed pigs 2 mg FB1/
kg/day as culture material for 5 weeks and
then vaccinated them with a killed pseudora-
bies virus vaccine (PRV/Marker Gold-KV;
SyntroVet, Inc., Lenexa, KS, USA). There
were no signiﬁcant changes in the PrV stimu-
lation index, response to phytohemagglutinin,
or PrV antibody titers, in total lymphocyte
numbers, nor in numbers of CD3+, CD4+,
CD8+, or CD4+/8+ subpopulations (60).
Therefore, fumonisin did not affect either the
cell-mediated or humoral immune responses
in our study.
We also examined the effect of fumonisins
on nonspeciﬁc immunity. The accumulation
of membranous material in pulmonary
intravascular macrophages and Kupffer cells,
Figure 2. Lung from a pig that died from porcine
pulmonary edema after ingesting corn naturally contami-
nated with fumonisins. Edema is characterized by mas-
sive dilation of lymphatics within the interlobular septa
(arrows). In control lung, lymphatics are barely
discernible. Hematoxylin and eosin ￿ 100. 
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and to a lesser extent in alveolar macrophages
(29), suggested an effect of fumonisin on
macrophage function. Pulmonary intravascu-
lar macrophages are phagocytic cells that
adhere to the pulmonary capillary endothe-
lium. In pigs as well as in ruminants, pul-
monary intravascular macrophages are
numerous and are the primary cells responsi-
ble for clearing particulates from the circula-
tion, as opposed to the hepatic Kupffer cells,
which are responsible for clearance in most
species such as dogs, humans, and rodents
(61). Pigs fed a sublethal dose of fumonisin
from culture material for 7 days had
decreased clearance of bacteria (Pseudomonas
aeruginosa) and particulate material (copper
phthalocyanine as Monastral blue) from the
pulmonary circulation (62). Therefore, we
investigated phagocytosis by alveolar
macrophages using ﬂow cytometry of ﬂuores-
cein isothiocyanate (FITC)-labeled opsonized
Salmonella typhimurium. In an in vitro study,
we demonstrated dose-dependent fumonisin
inhibition of S. typhimurium phagocytosis by
a murine monocyte/macrophage (RAW264)
cell line exposed to FB1 at ≥ 25 mM for 24 hr
(63). Similar ﬁndings were obtained in RAW
cells using luminal-dependent chemilumines-
cence (64). In addition, phagocytosis of S.
typhimurium was decreased in alveolar
macrophages from pigs fed fumonisin from
culture material and isolated before pulmonary
edema developed (63). Therefore, fumonisin
exposure can suppress an important surveil-
lance system (nonspeciﬁc immunity) in pigs.
Decreased ability of pulmonary intravascular
macrophages to remove bacteria from the cir-
culation and of alveolar macrophages to
remove bacteria inhaled into the lung could
predispose pigs to infectious diseases, both pul-
monary and systemic. In fact, an association
between increased risk of infectious disease and
fumonisin-contaminated swine food has been
reported (17). Additional studies are
needed to determine the clinical relevance
of these findings. 
Pathogenesis of Porcine
Pulmonary Edema
The pathogenesis of fumonisin-induced
pulmonary edema must consider the pul-
monary and cardiovascular ﬁndings presented
above. In vivo pulmonary changes relevant to
the pathogenesis of fumonisin-induced pul-
monary edema include histologic evidence of
pulmonary interstitial edema, pulmonary
capillary endothelial alterations (16), and the
lack of effect on the permeability of pul-
monary endothelium in vivo (35). The ultra-
structural ﬁndings raised questions regarding
the role of the endothelial changes in the
development of PPE, the involvement of
altered sphingolipids in the development of
the endothelial lesion, and functional pertur-
bations in the affected endothelium. The in
vitro studies in which increased permeability
was shown are considered not physiologically
relevant (51). The rapid and dose-dependent
increases in sphingoid bases observed in lung,
in vivo and in vitro, and in endothelial cells in
vitro (16,38,42,51) must be considered. 
The ultrastructural accumulation of
membranous material in porcine pulmonary
capillary endothelial cells is believed to be
specifically induced by FB1 and caused by
altered sphingolipid metabolism, resulting in
disruption of the endoplasmic reticulum and
Golgi (16). However, the role of these
endothelial changes in the development of
PPE is unclear since only a few affected cells
underwent degeneration and cell death in
pigs with pulmonary edema. Only a signifi-
cant loss of capillary endothelial cells would
lead to increased permeability and alveolar
edema. Increased permeability was not
observed in vivo, and interstitial rather than
alveolar edema is the most prominent
morphologic change. However, this capillary
endothelial change would cause thickening of
the alveolar-capillary membrane and thus
contribute to the oxygen diffusion abnormali-
ties induced by the edema that lead to sys-
temic arterial hypoxemia. Other functional
perturbations in the affected endothelium
cannot be ruled out.
The cardiovascular hemodynamic changes
induced by FB1 in swine and documented by
our laboratory indicate that FB1 is a negative
inotropic agent that decreases the cardio-
vascular reserve of pigs (9,10,35,37). The
decreased cardiac contractility appears
responsible for increasing pulmonary artery
wedge pressure (an index of pulmonary capil-
lary pressure) and the subsequent pulmonary
edema caused by left-sided heart failure. We
propose that the fumonisin-induced increase
in heart and/or serum sphingosine concentra-
tion inhibits the L-type calcium channels of
cardiac myocytes, thereby decreasing Ca2+-
induced Ca2+ release and thus decreasing
cardiac contractility.
We also observed a terminal increase in
oxygen consumption (10,35). The cellular
mechanism for the increased oxygen con-
sumption in fumonisin-treated pigs may be
due to sphingosine-mediated inhibition of L-
type Ca2+ channels or sphingosine-1-phos-
phate activated Ca2+ release from the
endoplasmic reticulum, increasing the occur-
rence of futile cycles. Alternatively, inhibi-
tion of protein kinase C may result in the use
of energetically less efficient pathways for
cellular metabolism.
Current Issues
During the USDA’s National Animal Health
Monitoring System (NAHMS) Swine ’95
study, mycotoxins (aflatoxins, zearalenone,
deoxynivalenol, and fumonisins) were
detected in nearly 77% of the corn-based
rations and 45% of noncorn-based rations
such as milo and barley. Fumonisins are of
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Figure 3. Liver from a control (A) pig and a pig that died from porcine pulmonary edema (B) after ingesting corn naturally contaminated with fumonisins. In control liver, the cen-
tral vein (lower left) is surrounded by hepatocytes arranged in cords separated by sinusoids. In the treated pig, the hepatic cords are disorganized, and hepatocytes contain vac-
uoles and apoptotic bodies (arrow). A hepatocyte is undergoing mitosis (arrowhead). Hematoxylin and eosin ￿ 300.
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special concern because of their widespread
occurrence, potential carcinogenicity, and
species-speciﬁc effects. Although much infor-
mation is available regarding the effects of
fumonisins from in vivo and in vitro studies,
these significant gaps in our knowledge
remain to be addressed:
• Pathogenesis of pulmonary edema
• Mechanism of cardiovascular and
immune effects
• Dose–response studies for cardiovascular,
hepatic, and immune effects
• In vivo challenge studies for immunosup-
pression
• Reproductive effects
• Interaction with other mycotoxins/dis-
eases
• Hypercholesterolemia: pathogenesis and
potential role in atherosclerosis.
When considering the effects of fumon-
isins in swine, the following areas need to be
addressed: swine safety and productivity, the
safety of swine-derived products consumed
by humans, and the potential role of fumon-
isins in human disease. It is well known that
fumonisins at high doses can cause morbid-
ity and mortality in pigs and horses. In the
United States, the 1989 corn crop was heav-
ily contaminated with fumonisins, and large
numbers of pigs died of PPE; abortions also
were reported. In 1998, the southern U.S.
corn crop also was heavily contaminated
with fumonisins and aflatoxins; however,
outbreaks of PPE were not reported, perhaps
because of a change in feeding practices. In
1993, the Mycotoxin Committee of the
American Association of Veterinary
Laboratory Diagnosticians (AAVLD) recom-
mended that the total swine diet contain less
than 10 ppm FB1 [quoted in Miller et al.
(65)]. In addition, corn screenings, usually
heavily contaminated with fumonisins, are
no longer commonly used as animal feed.
However, outbreaks of PPE continue to be
reported sporadically from Europe. Equine
leukoencephalomalacia continues to occur
sporadically within the United States, pre-
sumably because horses are much more sensi-
tive to the toxic effects of fumonisins than
are swine and cattle. Of greater economic
concern in swine are the low-dose effects of
fumonisins, which include subclinical
hepatic disease; altered carcass quality;
adverse immune effects with potential predis-
position to infectious diseases; and potential
interactions with other toxins, including
mycotoxins and other diseases. Potential
reproductive effects also need further study
in swine. 
Mycotoxins present in animal feed can
enter the human food supply as residues pre-
sent in animal tissues and other animal-
derived products. The primary current
public health concern with fumonisins is
cancer because of the induction of tumors in
laboratory animals (66) and the epidemio-
logic association of fumonisins with eso-
phageal cancer in humans (18). Although
FB1 has poor bioavailability in swine, the lit-
tle that is absorbed undergoes extensive distri-
bution and can remain in the body for an
extended time. FB1 and its metabolites accu-
mulate primarily in the liver and to a lesser
extent in the kidney, and accumulation
appears to increase with exposure time
(27,28). This suggests that market-weight
pigs could contain residual levels even if only
exposed to low dietary concentrations.
However, because fumonisin residues in gen-
erally edible products are low and organ
meats typically constitute a very small per-
centage of the diet, it is believed that pork
products do not represent a public health
concern when swine are exposed to fumon-
isins at or below the guidelines (10 ppm) set
by the AAVLD (65). In addition to fumon-
isin residues in swine products, the effect of
fumonisins on the swine immune system also
must be considered in evaluation of fumon-
isins for their food safety. The potential
increase in susceptibility of swine to infec-
tious agents, such as Salmonella sp., which has
become one of the top foodborne health con-
cerns in the United States, is of importance.
FB1 has been shown to increase susceptibility
to Escherichia coli infection in pigs (67). 
Swine are physiologically similar to
humans and are used widely as models for
human diseases, particularly cardiovascular
disease (68). Understanding the pathophysi-
ology of fumonisin toxicosis in swine is
important not only in the context of pre-
vention and therapy of outbreaks of PPE,
but also in understanding whether human
exposure to fumonisins may have adverse
chronic effects. 
Low-dose, long-term studies are needed
to investigate further the cardiovascular and
pulmonary alterations induced by fumon-
isins in swine. In addition, further investiga-
tion of hypercholesterolemia and its
potential role in the development of athero-
sclerosis is needed. FB1 increases serum cho-
lesterol concentration in all species
examined. This is one of the earliest
detectable serum biochemical change and
has been reported at dietary concentrations
as low as 1 ppm in swine (44). Moreover,
long-term feeding of FB1 as culture material
to nonhuman primates (Vervet monkeys)
caused hypercholesterolemia and an athero-
genic plasma lipid profile (69). The poten-
tial contribution of dietary fumonisins to
cardiovascular disease in humans must be
examined given that the pig is the best
model for cardiovascular disease and that
hypercholesterolemia is an independent risk
factor for heart disease in humans. 
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